Changeflow GovPing Pharma & Life Sciences

Recent changes

GovPing monitors 142 sources for this role across Guidance, Enforcement, Rule, Notice, and Consultation, out of 2,503 total sources on the platform. The past week saw 602 changes across these sources.

FDA issued a Warning Letter to Purolea Cosmetics Lab for CGMP violations, while also warning Dry Springs Pharmacy for unlawful opioid sales. A Class I recall of Philips Trilogy Evo ventilators highlights a serious device safety issue. The Class I recall of Draeger Atlan A350 anesthesia workstations further underscores critical equipment risks.

Favicon for changeflow.com

CLDN18.2 binding molecule patent granted to Sanyou

CLDN18.2 binding molecule patent granted to Sanyou

Routine Notice
Favicon for changeflow.com

Monoclonal antibody matrix metalloproteinase-1 patent granted

USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.

Routine Notice Intellectual Property
Favicon for changeflow.com

TfR1 Humanized Antibodies and Cancer Treatment Methods

The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.

Routine Notice Intellectual Property
Favicon for changeflow.com

GPC3 antibody patent - methods of use for cancer treatment

The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.

Routine Notice Intellectual Property
Favicon for changeflow.com

6-Thio-dG Treatment for Pediatric Brain Tumors

The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.

Routine Notice Intellectual Property
Favicon for www.regulations.gov

CDC Drug Overdose Data Collection - Comment Request

The CDC has issued a consultation document requesting public comments on drug overdose data collection methods and reporting requirements. The document seeks input on proposed data collection standards that state and local health departments would use to report overdose surveillance data to the CDC. Comments are due by June 8th.

Priority review Consultation Public Health
Favicon for www.regulations.gov

CDC NNDSS Surveillance Update, Comment Deadline June 8

The CDC published a surveillance update to the National Notifiable Diseases Surveillance System (NNDSS), with public comments requested by June 8. The NNDSS is a nationwide system for tracking notifiable diseases reported by state and territorial health departments. Healthcare providers, laboratories, and public health authorities submitting disease data to CDC should review the proposed changes and submit feedback.

Routine Consultation Public Health
Favicon for changeflow.com

Quorum Sensing Compositions and Methods for Microbial Community Modulation

USPTO granted patent US12594307B2 to The Regents of the University of California for quorum sensing compositions and methods for modulating bacterial quorum sensing. The patent covers engineered bacterial strains with multiple activator polypeptide-encoding sequences and methods for tunable dynamics in microbial communities. Inventors include Jeff Hasty, Arianna Miano, and Michael Julius Liao, with applications spanning synthetic biology and therapeutic development.

Routine Notice Intellectual Property
Favicon for changeflow.com

Virus-like Particles Patent Granted to University of Denver

The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.

Routine Notice Intellectual Property
Favicon for changeflow.com

Temperature-Optimized Bacillus Strains Patent Grant

The USPTO granted patent US12593849B2 to Chr. Hansen A/S on April 7, 2026, covering new strains of Bacillus paralicheniformis with improved growth rates and plant growth promoting properties. The patent names six inventors including Patricia Dominguez Cuevas and Lars Moelbak, with 21 claims. Filing date was August 28, 2020, under application number 17638152.

Routine Notice Intellectual Property

Showing 811–820 of 3,591 changes

1 80 81 82 83 84 360
RSS

Get daily alerts for pharma & life sciences

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Filters

142 official sources tracked

Regs.gov: Food and Drug Administration

Updated 4m ago

USPTO Trademarks - Pharmaceuticals (Class 005)

Updated 11d ago

USPTO Patent Applications - Pharma (A61K)

Updated 2d ago

USPTO Patent Applications - Biotech (C12N)

Updated 17h ago

ClinicalTrials.gov

Updated 24m ago

USPTO Patent Applications - Peptides (C07K)

Updated 2d ago

USPTO Patent Applications - Organic Chemistry (C07D)

Updated 4d ago

USPTO Patent Applications - Therapeutics (A61P)

Updated 2d ago

USPTO Patent Grants - Therapeutics (A61P)

Updated 19m ago

USPTO Patent Grants - Organic Chemistry (C07D)

Updated 12h ago

USPTO Patent Grants - Peptides (C07K)

Updated 7h ago

ANSM Drug & Device Safety Alerts

Updated 4m ago

FDA: Drug Recalls Class II

Updated 8d ago

FR: National Institutes of Health

Updated 33m ago

Health Canada Recalls & Safety Alerts

Updated 6m ago

Regs.gov: Centers for Medicare and Medicaid Services

Updated 22h ago

FR: Health and Human Services Department

Updated 15m ago

FR: Food and Drug Administration

Updated 33m ago

FDA Warning Letters

Updated 3m ago

CPSC Product Recalls

Updated 13d ago

FR: Drug Enforcement Administration

Updated 12d ago

MHRA Guidance & Safety

Updated 32m ago

WHO News

Updated 3h ago

CMS Newsroom

Updated 5d ago

FR: Centers for Disease Control and Prevention

Updated 1d ago

FR: Centers for Medicare & Medicaid Services

Updated 17m ago

Regs.gov: Occupational Safety and Health Administration

Updated 20h ago

DEA Press Releases

Updated 27m ago

EPO Patent Bulletin - Pharma (A61K)

Updated 23m ago

HSA Singapore Announcements

Updated 22m ago

FDA Medical Device Recalls

Updated 1m ago

DEA Public Safety Alerts

Updated 6d ago

Regs.gov: Animal and Plant Health Inspection Service

Updated 5d ago

FDA Recalls & Safety Alerts

Updated 17h ago

Regs.gov: Centers for Disease Control and Prevention

Updated 23h ago

Saudi SFDA News

Updated 21h ago

Regs.gov: Food Safety and Inspection Service

Updated 11d ago

HHS OIG Reports & Publications

Updated 12d ago

FR: Health Resources and Services Administration

Updated 6m ago

ANSM France News

Updated 11m ago

FDA Press Releases

Updated 24h ago

WV Board of Pharmacy

Updated 10d ago

USP Compendial Notices

Updated 12d ago

NH Board of Pharmacy Actions

Updated 12d ago

BfArM Drug Safety Communications

Updated 3d ago

EPO Patent Bulletin - Therapeutics (A61P)

Updated 37m ago

PMPRB

Updated 25m ago

MS Board of Pharmacy News

Updated 27d ago

LA Board of Pharmacy News

Updated 27d ago

UK VMD

Updated 19m ago

FDA Debarment List

Updated 9d ago

FDA Drug Recalls Class I

Updated 19d ago

FDA AI-Enabled Medical Devices

Updated 23d ago

GA Board of Pharmacy Board Orders

Updated 22d ago

KS Board of Pharmacy Newsletters

Updated 20d ago

NICE Technology Appraisals

Updated 7d ago

FDA Guidance Documents

Updated 3h ago

ECHA News

Updated 14d ago

WI Pharmacy Board Newsletters

Updated 26d ago

FDA Untitled Letters

Updated 23d ago

Frequently asked questions

What does this feed cover?

FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.

Who is this for?

Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.

How often is this updated?

GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.

Does this cover EMA and international regulators?

Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.

How is this different from AgencyIQ?

AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.

Is GovPing free?

Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.

Need to monitor something else?

GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.

Get Pharma & Life Sciences alerts

Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.

Free. Unsubscribe anytime.